KRAS and cancer: The present findings suggest that the targeted inhibition of downstream effectors (e.g., RAF, MEK, ERK, PI3K, AKT, and mTOR) or combinations thereof may be a more rational and effective approach for the treatment of cancers driven by KRAS Q61H.